ACIP expands PCV to adults 50+; cost-effectiveness supports; Pfizer 25vPnC data

CEA backs ACIP Oct 2024 vote expanding PCV to all 50+. PCV21 more favorable than PCV20; two-dose (50+65) strategy improves outcomes at higher cost. Workflow changes (PDSA, pharmacists, EHR) boost uptake 44.1%. Pfizer 25vPnC shows strong early trial data for adults 50+.